Nectin-4 CDx Antibody: Core Biomarker Reagent for Solid Tumor Targeted Therapy Preclinical Research
1. Molecular Architecture and Tissue Expression Profiles of Nectin-4 (PVRL4)
Nectin-4, also annotated as PVRL4 (poliovirus receptor-related protein 4), belongs to the immunoglobulin-like Nectin superfamily sharing sequence homology with poliovirus cellular receptors. This single-pass transmembrane polypeptide contains 510 amino acid residues with a calculated molecular weight of 55.5 kDa and distinct modular structural domains.
Its linear architecture includes an N-terminal signal peptide mediating membrane trafficking, three tandem extracellular Ig-like folds for intercellular adhesion, a short transmembrane linker, and a C-terminal cytoplasmic segment carrying conserved afadin-binding PDZ motifs. The cytoplasmic domain mediates cytoskeleton remodeling and downstream signal transduction upon homotypic or heterotypic cell adhesion.
Physiological expression of Nectin-4 concentrates within embryonic and placental tissues, with minimal detectable transcription across fully differentiated adult somatic tissues. Multiple solid tumor subtypes display robust ectopic Nectin-4 upregulation including thyroid, esophageal, gastric, gallbladder, breast, colorectal and urothelial carcinoma. CDx-grade anti-Nectin-4 antibodies from ANT BIO PTE. LTD. enable quantitative IHC profiling to stratify tumor populations for ADC intervention mechanistic research.
2. Multi-Branched Signaling Cascades Regulated by Nectin-4 in Tumor Progression
Nectin-4 drives malignant proliferation, angiogenesis and metastatic dissemination by modulating interconnected kinase axes centered on the PI3K/AKT signaling module. Hypoxia-triggered proteolytic cleavage releases soluble Nectin-4 ectodomains that bind endothelial integrin β4 to activate Src, PI3K, Akt and eNOS and stimulate de novo vascular sprouting within tumor stroma.
In breast carcinoma cell models, Nectin-4 forms functional complexes with ERBB2 to amplify PI3K/AKT-mediated DNA replication, while soluble Nectin-4 concurrently activates Wnt/β-catenin to accelerate invasive migration. Separate signaling axes mediated by Nectin-4 include PI3K/AKT/NF-κB for osteosarcoma progression and Rac1-dependent pathways driving gastric and gallbladder tumor expansion.
Additional cross-talk networks involve JAK2-STAT5a (prostate cancer growth), JAK-STAT3/SOX2 (breast cell proliferation), and CXCR4/CXCL12-LYVE-1 (lymphangiogenesis and distant metastasis). Anti-Nectin-4 antibody IHC quantification correlates total protein abundance with pathway activation intensity and intrinsic metastatic potential for comparative preclinical analysis.
3. Preclinical Application of Nectin-4 Antibodies in Urothelial Carcinoma Research
Urothelial carcinoma represents the primary solid tumor subtype characterized by widespread Nectin-4 overexpression, correlating with adverse pathological markers such as high tumor grade, lymphovascular invasion and elevated mortality rates in patient tissue cohorts. Antibody-drug conjugates targeting Nectin-4 serve as standard experimental agents for advanced urothelial tumor intervention models.
ADC molecular constructs combine anti-Nectin-4 monoclonal fragments with microtubule inhibitors via protease-cleavable linkers. Upon membrane binding and cellular endocytosis, lysosomal acidic hydrolysis releases cytotoxic payloads to block tubulin polymerization and trigger tumor cell apoptotic arrest.
Validated Nectin-4 recombinant antibodies from the Starter sub-brand under ANT BIO PTE. LTD. generate reproducible IHC staining on FFPE urothelial tissue sections, supporting retrospective stratification of tumor subgroups to compare ADC response phenotypes across high and low Nectin-4 expression preclinical cohorts.
4. Nectin-4 Antibody Utilization in Digestive Tract Tumor Mechanism Studies
Colorectal tumor Nectin-4 engages integrin β1 to facilitate intratumoral angiogenesis and confers intrinsic resistance to 5-fluorouracil treatment regimens in cell culture and xenograft models. Transient Nectin-4 gene silencing attenuates proliferative and migratory phenotypes, establishing target downregulation as a viable experimental intervention strategy.
Elevated Nectin-4 expression within esophageal carcinoma tissue correlates with shortened survival endpoints and enhances cellular migratory capacity in in vitro scratch assays. Gastric tumor Nectin-4 protein levels align sequentially with advancing TNM pathological staging, while gallbladder carcinoma progression relies on Nectin-4 mediated Rac1 kinase activation.
CDx-grade Nectin-4 antibodies enable standardized IHC signal quantification across all digestive tract tumor subtypes, generating continuous biomarker readouts to correlate expression magnitude with therapeutic response profiles in preclinical compound screening pipelines.
5. Nectin-4 Antibody Application in Reproductive and Respiratory Tumor Preclinical Workflows
Cervical carcinoma Nectin-4 upregulation contributes to acquired 5-FU chemoresistance by modulating angiogenic signaling and DNA damage repair pathways. Ovarian tumor spheroid formation and sustained proliferative activity depend on robust Nectin-4 transcription, directly altering cellular response to standard cytotoxic compound exposure.
In breast tumor research, circulating soluble Nectin-4 serves as measurable supernatant biomarker and synergizes with ERBB2 to hyperactivate PI3K/AKT cascades. Non-small cell lung carcinoma tissue displaying elevated Nectin-4 exhibits heightened invasive capacity and shortened survival metrics in longitudinal preclinical monitoring.
Starter anti-Nectin-4 antibody reagents support multi-tissue IHC staining protocols to stratify reproductive and respiratory tumor subgroups, enabling comparative evaluation of single-agent and combined targeted intervention phenotypes across divergent solid tumor model systems.
6. Core Performance Specifications of Starter Nectin-4 Recombinant CDx Antibody
ANT BIO PTE. LTD.’s proprietary Starter platform produces fully sequence-defined recombinant rabbit anti-Nectin-4 mAb (SDT-277-314-1, catalog S0B2312) optimized for multi-assay tumor biomarker research workflows with four distinct functional strengths.
-
Isoform-Specific Binding Specificity
Validated via IHC, Western blot and flow cytometry against all four Nectin paralogs, with negligible off-target cross-reactivity to Nectin-1, Nectin-2 and Nectin-3. Optimized antibody dilution yields sharp membranous and cytoplasmic tumor staining with minimal non-specific background noise on FFPE tissue slides. -
Consistent Recombinant Batch Performance
Recombinant expression eliminates hybridoma genetic drift risks, delivering uniform binding affinity across sequential production lots suitable for large-scale tissue microarray retrospective research spanning multiple experimental batches. -
Established ADC Target Biomarker
Nectin-4 functions as the primary protein biomarker for Enfortumab Vedotin ADC preclinical testing, with approximately 90% of metastatic urothelial tumor tissue presenting robust antibody-detectable antigen expression alongside triple-negative breast, NSCLC, esophageal and ovarian carcinoma models. -
Multi-Platform Functional Compatibility
Comprehensive validation confirms stable staining signals across paraffin IHC, WB, flow cytometry and confocal immunofluorescence to satisfy diverse solid tumor biomarker quantification and target antibody screening experimental designs.
7. Cross-Disciplinary Extended Preclinical Research Scenarios
Beyond solid tumor ADC biomarker stratification, Starter Nectin-4 antibodies support viral entry mechanism research measuring PVRL4-mediated morbillivirus cellular uptake and embryonic developmental tissue adhesion profiling. Metastasis research groups utilize serial IHC quantification to track Nectin-4 expression shifts along primary-to-secondary tumor progression gradients across patient-derived xenograft tissue cohorts.
Immunotherapy combinatorial screening projects combine Nectin-4 staining with immune checkpoint marker panels to characterize the crosstalk between ADC cytotoxicity and intratumoral immune cell infiltration phenotypes across urothelial, breast and lung tumor preclinical models.
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.
Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.
